
    
      This study is designed to evaluate the safety, tolerability, pharmacokinetics and
      pharmacodynamics of orally administered GB2064 a LOXL-2 inhibitor over 9 months. Subjects
      will receive doses of GB2064, given twice per day to participants with primary or secondary
      Myelofibrosis
    
  